CAS Medical Systems, Inc. (CASM) Announces Publication of Study Using FORE-SIGHT(R) to Improve Identification of Children With Sickle Cell Disease at Highest Risk for Neurologic Injury in Pediatric Blood and Cancer Journal
6/28/2012 9:25:13 AM
BRANFORD, Conn., June 28, 2012 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) (CASMED) today announced the online early publication of the study "Cerebral Tissue Hemoglobin Saturation in Children With Sickle Cell Disease" in the Pediatric Blood and Cancer journal. In an NIH-funded study, researchers used CASMED's FORE-SIGHT® Oximeter to measure absolute oxygen saturation levels in the brain of children with sickle cell disease (SCD) and found that cerebral oximetry is a useful non-invasive tool to identify those who are at risk for brain injury and could help guide neuroprotective therapies for these patients.
comments powered by